knowledge -WSS

knowledge

author：focus 2025-10-01 12:25:31 - browse：19959

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Readout Newsletter: Beam, Prozac, "TechBio" and more

explore

WSS

Diversify hospital leadership teams to protect BIPOC patient health

The Sacklers, horror, and ‘The Fall of the House of Usher’

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Medicare Advantage isn’t working — for anyone

Childhood vaccination ad campaign launches in the U.K.

Using force crossed my mind when examining a defiant young patient

knowledge

knowledge

focus

Bright Health sells Medicare Advantage business to Molina

MoonLake credibility takes another hit with mid

State Dept. review finds Biden bears some blame for Afghanistan failures

Extreme heat events are a public health emergency

After affirmative action ruling, medical educators look to 'holistic review'

Neuroscience renaissance leads to new crop of psychiatric drugs

After affirmative action ruling, medical educators look to 'holistic review'

STAT Executive Editor Rick Berke on STAT's 8th birthday

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

MoonLake credibility takes another hit with mid

focus

FDA approves Recor Medical high blood pressure device

Medicare Advantage isn’t working — for anyone

Free speech concerns arise in wake of journal editor Eisen's firing

A clever new way to fix Medicaid and graduate medical education

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Medicare will require more price transparency from hospitals

explore

explore

Wikipedia

explore